Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Elgemtumab |
Trade Name | |
Synonyms | LJM716|LJM-716 |
Drug Descriptions |
Elgemtumab (LJM716) is a monoclonal antibody that targets ErbB3 (Her3) and prevents its transition into an active conformation, resulting in inhibition of ligand-dependent and ligand-independent downstream signaling and decreased tumor cell proliferation (PMID: 23928993, PMID: 27942917). |
DrugClasses | HER3 (ERBB3) Antibody 23 |
CAS Registry Number | 1512559-37-3 |
NCIT ID | C101895 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Alpelisib + Elgemtumab | Alpelisib Elgemtumab | 0 | 1 |
Alpelisib + Elgemtumab + Trastuzumab | Alpelisib Elgemtumab Trastuzumab | 0 | 1 |
Buparlisib + Elgemtumab | Buparlisib Elgemtumab | 0 | 0 |
Elgemtumab | Elgemtumab | 0 | 0 |
Elgemtumab + Neratinib | Elgemtumab Neratinib | 0 | 0 |
Elgemtumab + Trastuzumab | Elgemtumab Trastuzumab | 0 | 1 |